Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene

Circulation Research

Volumn 84, Issue 12, 1999, Pages 1416-1421

  Freedman, Jane E ^a   Sauter, Ryan ^c   Battinelli, Elisabeth M ^c   Ault, Kenneth ^c   Knowles, Cathy ^c   Huang, Paul L ^b   Loscalzo, Joseph ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NONE

Author keywords

Mice; Nitric oxide synthase; Platelet; Selectin

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; GENE MUTATION; HEMOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOGENESIS;

EID: 0033603292     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.12.1416     Document Type: Article

References (34)

1. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992;85:2284-2290.
2. Radomski MW, Palmer MJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148:1482-1489.
3. Stamler J, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, Cooke JP, Loscalzo J. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989;65:789-795.
4. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol. 1990;259:H804-H812.
5. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992;90: 1718-1725.
6. Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of nitric oxide/endothelium-derived relaxing factor on platelet surface glycoproteins. Am J Physiol. 1996;270: H1640-H1648.
7. Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest. 1995;96:394-400.
8. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996;97:979-987.
9. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995;57:2049-2055.
10. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995;125:370-377.
11. Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol. 1996;27:154-158.
12. Pigazzi A, Fabian A, Johnson J, Upchuch GR, Loscalzo J. Identification of nitric oxide synthases in human megakaryocytes and platelets. Circulation. 1995:92:I-365. Abstract.
13. Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun. 1993;194:960-965.
14. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-5197.
15. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF Jr, Michelson A. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100:350-356.
16. Chen LY, Mehta JL. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther. 1996; 276:253-257.
17. Simon DI, Stamler JS, Loh E, Loscalzo J, Frances SA, Creager MA. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol. 1995;26:339-342.
18. Bodzenta-Lukaszyk A, Gabryelewicz A, Lukaszyk A, Bielawiec M, Konturek JW, Domschke W. Nitric oxide synthase inhibition and platelet function. Thromb Res. 1994;75:667-672.
19. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
20. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699-708.
21. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JFJ, Vita JA. Impaired platelet production of nitric oxide in patients with unstable angina. Circulation. 1998;98:1481-1486.
22. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
23. Shesely E, Maeda N, Kim H, Desai M, Krege J, Laubach V, Sherman P, Sessa W, Smithies O. Elevated blood pressure in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996;93:13176-13181.
24. Steudel W, Ichinose F, Huang P, Hurford W, Jones R, Bevan J, Fishman M, Zapol W. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS3) gene. Circ Res. 1997;81:34-41.
25. Hawiger JS, Parkinson S, Timmons S. Prostacyclin inhibits mobilization of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature. 1980;283:195-198.
26. Ichimori K, Ishida H, Fudahori M, Nakazawa H, Murakami E. Practical nitric oxide measurement employing a nitric oxide-selective electrode. Rev Sci Instrum. 1994;65:1-5.
27. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol (Lond). 1963;168:178-195.
28. Freedman JE, Farhat J, Loscalzo J, Keaney JF Jr. α-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996;94:2434-2440.
29. Ulich TR, del Castillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood. 1995;86:971-976.
30. Broekman MJ, Eiroa AM, Marcus AJ. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism. Blood. 1991;78: 1033-1040.
31. Holmsen H, Dangelmaier C. Measurement of secretion of serotonin. Methods Enzymol. 1989;169:205-210.
32. Chen L, Salafranca N, Mehta J. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol. 1997;273: H1854-H1859.
33. 2 synthase. Arch Biochem Biophys. 1997;347:174-180.
34. Santos MT, Valles J, Marcus AJ, Safier M, Broekman J, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest. 1991;87:571-580.